tbuckley/cabot-search huggingface dataset:
FRI0095 Anti-tnfΑ versus rituximab in refractory peripheral ulcerative keratitis associated to rheumatic diseases. multicenter study of 24 patients
Authors: L.C. Domínguez Casas, V. Calvo-Río, O. Maíz-Alonso, A. Blanco, E. Beltran, L. Martinez Acosta, M.C. Alvarez de Buergo, E. Rubio-Romero, D. Díaz-Valle, R. López-González, A. García- Aparicio, A. Juan Mas, E. Pons, R. Demetrio-Pablo, N. Vegas-Revenga, R. Blanco, M. Gonzalez-Gay
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> This study shows that treatment with biologic drugs, including ant-TNF drugs, in NION associated to IMIDs, refractory to conventional treatment, seems to be effective. These results must be confirmed in prospective and randomised trials. <h3>Objectives</h3> Our aim was to compare anti-TNFα vs Rituximab (RTX) in refractory PUK. <h3>Methods</h3> Multicenter study of 24 patients with PUK. All of them presented inadequate response to corticosteroids and at least 1 systemic traditional immunosuppressive drug. Anti-TNFα were used in 17 patients: Adalimumab (n=9) 40 mg/sc every 1–2 weeks, infliximab (IFX) (n=7) 3–5 mg/kg iv/4–6 weeks, etanercept (n=1) 50 mg/week. RTX was used in 7 patients 1–2 g i.v. every 6 or 12 months. The main outcomes were Best Corrected Visual Acuity (BCVA), signs of inflammation (scleritis and episcleritis), progression to corneal thinning, central keratolysis and ocular perforation. <h3>Results</h3> We studied 24 patients/32 affected eyes. The underlying diseases in the anti-TNFα group were Rheumatoid Arthritis (RA) (n=14), Psoriatic Arthritis (n=2) and Behçet Disease (n=1); and in the RTX group: RA (n=5), granulomatous polyangiitis (n=1) and microscopic polyangiitis (n=1). At baseline there were no significant differences between both groups in general features or in ocular involvement<b> (</b>table 1<b>).</b> Before biologic therapy they had received the following systemic drugs (anti-TNFα vs RTX) i.v. methylprednisolone (2 vs 4), doxycycline (7 vs 1), ascorbic acid (2 vs 0), MTX (11 vs 4), AZA (1 vs 2) and others (7 vs 3). In addition,10 patients, in both groups, had required surgery: amniotic membrane (n=5), penetrating keratoplasty (n=2), conjunctival resection (n=2), tissue adhesives (n=2), conjunctival flap (n=1) and lamellar keratoplasty (n=1). Once the treatment was initiated the ocular outcome was similar (table 1<b>).</b> After a mean follow-up of 22.53±22.60 (anti-TNFα) and 22.28±8.28 months with RTX the following severe side effects were observed: supraventricular tachycardia (n=1) with RTX and pulmonary tuberculosis (n=1) with IFX. <h3>Conclusions</h3> In this study, anti-TNFα therapy and RTX were equally effective for the treatment of peripheral ulcerative keratitis associated to rheumatic diseases refractory to conventional treatment. <h3>Disclosure of Interest</h3> None declared
THU0652 Comparative cost per response for four clinical outcomes of tocilizumab monotherapy versus adalimumab monotherapy in a head-to-head randomised double-blind superiority trial (ADACTA) in patients with rheumatoid arthritis
Authors: J. Best, J. Pei
Journal: Annals of the Rheumatic Diseases (2018)

Background: The cost-effectiveness of different biologic therapies is an important component in guiding treatment decisions for patients with rheumatoid arthritis (RA).Objectives: To compare drug and adverse event costs and cost per successful clinical response with tocilizumab (TCZ) monotherapy vs adalimumab (ADA) monotherapy in patients with RA.Methods: Patients in the ADACTA trial 1 were randomised to either TCZ 8 mg/kg intravenously every 4 weeks or ADA 40 mg subcutaneously every 2 weeks as monotherapy for 24 weeks.Drug costs of $397.71/80mg vial for TCZ (plus $136 administration cost per infusion) and $2220.62/40mg for ADA were based on Wholesale Acquisition Costs (WAC) drug prices (July 2017).Outcomes included patient-level drug costs and cost of hospitalisation due to adverse events, and cost per response.Cost per response was calculated by dividing the mean drug plus administration cost by the proportion of patients achieving Disease Activity Score-28 joints (DAS28) <2.6 (remission) or American College of Rheumatology response criteria 20%/50%/70% (ACR20/ACR50/ACR70).The proportions of patients achieving DAS28 <2.6, ACR 20, ACR50 and ACR70 were 39.9%, 65.0%, 47.2% and 32.5% for TCZ, respectively, and 10.5%, 49.4%, 27.8% and 17.9% for ADA, respectively; p<0.0001, p=0.0038, p=0.0002, p=0.0023 for TCZ vs ADA, respectively.Hospitalisation costs were calculated using the daily hospital cost of $2433 (2017) and number of hospital days.Results: Among the 163 patients treated with TCZ and 162 with ADA, mean total drug and administration costs per patient over 24 weeks were $16,674.74 and $23,357.63,respectively.Mean drug and administration costs were lower per each clinical response achieved with TCZ compared with ADA (DAS28 <2.6: $41 791 vs $222,454; ACR20: $25 653 vs $47,283; ACR50: $35 328 vs $84,020; ACR70: $51 307 vs $130,490).The total hospital days/costs were 32/$77 856 for TCZ and 43/$1 04 619 for ADA.Conclusions: In this comprehensive comparative assessment, the cost to achieve all four clinical responses was lower for patients receiving TCZ than for ADA.
Long-Range Guidance of Spinal Commissural Axons by Netrin1 and Sonic Hedgehog from Midline Floor Plate Cells
Authors: Zhuhao Wu, Shirin Makihara, Patricia T. Yam, Shaun Teo, Nicolas Renier, Nursen Balekoglu, Juan Antonio Moreno-Bravo, Olav Olsen, Alain Chédotal, Frédéric Charron, Marc Tessier-Lavigne
Journal: Neuron (2019)
Abstract 168: Stress Dependent MicroRNA Mediate Crosstalk Between DNA Repair ′ Senescence & Angiogenic Signaling
Authors: Cristina Espinosa-Diez, RaeAnna Wilson, Namita Chaterjee, Clay Hudson, Rebbeca Ruhl, Erin Helms, Sudarshan Anand
Journal: Circulation Research (2017)

The endothelium is highly exposed to a myriad of stressors that can lead to endothelial dysfunction if persistent. One of the hallmarks of endothelial stress is increased DNA damage. MRN complex pl...
Abstract 19042: Role for Leptin Signaling in Experimental Group 2 Pulmonary Hypertension Due to Metabolic Syndrome
Authors: Benoit Ranchoux, François Potus, Alice Bourgeois, Valérie Nadeau, Roxanne Paulin, Ève Tremblay, Nancy Coté, Rami Abu-alhayja, Valérie Dumais, Renato Tadeu Nachbar, Lionel Tastet, Abdelaziz Dahou, Sandra Breuils-Bonnet, Annie-Christine Lajoie, André Marette, Philippe Pibarot, Jocelyn Dupuis, Olivier Boucherat, Steeve Provencher, Stephen Archer, Sébastien Bonnet
Journal: Circulation (2017)

Rationale: Pulmonary hypertension (PH) associated with heart failure (HF) with preserved ejection fraction (PH-HFpEF) affects over 50% of all patients with HFpEF and confers poor prognosis. Patholo...
The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019
Authors: A. D. Pranger, T. S. van der Werf, J. G. W. Kosterink, J. W. C. Alffenaar
Journal: Drugs (2019)

The inability to use powerful antituberculosis drugs in an increasing number of patients seems to be the biggest threat towards global tuberculosis (TB) elimination. Simplified, shorter and preferably less toxic drug regimens are being investigated for pulmonary TB to counteract emergence of drug resistance. Intensified regimens with high-dose anti-TB drugs during the first weeks of treatment are being investigated for TB meningitis to increase the survival rate among these patients. Moxifloxacin, gatifloxacin and levofloxacin are seen as core agents in case of resistance or intolerance against first-line anti-TB drugs. However, based on their pharmacokinetics (PK) and pharmacodynamics (PD), these drugs are also promising for TB meningitis and might perhaps have the potential to shorten pulmonary TB treatment if dosing could be optimized. We prepared a comprehensive summary of clinical trials investigating the outcome of TB regimens based on moxifloxacin, gatifloxacin and levofloxacin in recent years. In the majority of clinical trials, treatment success was not in favour of these drugs compared to standard regimens. By discussing these results, we propose that incorporation of extended PK/PD analysis into the armamentarium of drug-development tools is needed to clarify the role of moxifloxacin, gatifloxacin and levofloxacin for TB, using the right dose. In addition, to prevent failure of treatment or emergence of drug-resistance, PK and PD variability advocates for concentration-guided dosing in patients at risk for too low a drug-exposure.
THU0414 Association of the esophageal dilation and interstitial lung disease on chest high-resolution computed tomography in patients with in systemic sclerosis: a cross-sectional study
Authors: F. Salaffi, M. Di Carlo, M. Carotti, P. Fraticelli, A. Gabrielli, A. Giovagnoni
Journal: Annals of the Rheumatic Diseases (2018)

significant different, absolute number of the Treg cells trended to decrease in patients treated with immunosuppressive agents.The use of IL-2 can effectively up-regulate Treg cells as well as increase Th17 to a certain extent, which restores the balance of Th17/Treg cells, but the long-term effect needs further investigation.
Abstract MP35: Physical Activity Before and After Cancer Diagnosis and Total and Cause-Specific Mortality
Authors: Paulette D Chandler, Deirdre Tobias, Jule E Buring, I-Min Lee, Daniel Chasman, Kathryn T Hall, Nancy R Cook, Edward L Giovannucci, Aditi Hazra, Howard D Sesso
Journal: Circulation (2018)

Background: Given the increased prevalence of cancer survivors in the United States, it is imperative to define risk factors for potential reductions in total and cause-specific mortality. Physical activity (PA) represents a promising target for intervention. Design: We prospectively evaluated PA from questionnaires before and after cancer diagnosis with total and cause-specific mortality among 13,297 subjects diagnosed with invasive cancer combined from the Physicians’ Health Study (PHS) (n=6328), Physicians’ Health Study II (PHS II) (n=912), and Women's Health Study (WHS) (n=6057). WHS and PHS participants were free of baseline cancer; PHS II participants reported no active cancer at baseline. We ascertained PA before and after an incident cancer diagnosis based on reports on repeated follow-up questionnaires. Death was ascertained by medical records and death certificates. Cox regression estimated combined hazard ratios (HRs) of mortality by PA adjusted for age, randomized treatments, BMI, and other lifestyle/demographic factors. We evaluated the interaction between PA before and after cancer diagnosis by comparing PA ≤1 versus ≥2 times/wk. Results: The mean follow-up after cancer diagnosis was 8.0, 7.5, and 5.2 y for WHS, PHS, and PHS II, respectively, during which there were 5623 deaths (WHS, 2164; PHS, 3269; PHS II; 190). Higher PA before cancer diagnosis was associated with significantly lower mortality. Compared with PA ≤ once/wk, the HRs (95% CIs) associated with PA 2-4 and &gt;4 times/wk were 0.87 (0.82-0.93) and 0.88 (0.82-0.94) for total mortality; 0.77 (0.63-0.95) and 0.79 (0.62-0.997) for CVD mortality, and 0.90 (0.83-0.98) and 0.90 (0.83-0.98) for cancer mortality. Higher PA after cancer diagnosis was associated with significantly lower total and cancer mortality and non-significantly lower CVD mortality, with HRs (95% CIs) of 0.65 (0.58-0.72) and 0.66 (0.59-0.73) for total mortality; 0.78 (0.59-1.03) and 0.82 (0.61-1.10) for CVD mortality, and 0.66 (0.57-0.77) and 0.64 (0.55-0.74) for cancer mortality. There was a significant interaction of PA before and after cancer diagnosis for total (p int =0.02) and cancer (p int =0.007) mortality, but not CVD mortality (p int =0.38). Conclusions: Greater PA both before and after cancer diagnosis were significantly associated with lower total and cancer mortality. Higher PA before cancer diagnosis was also associated with lower CVD mortality. PA may be an important target for lower mortality after cancer diagnosis.
Dwjm-Adherence Induces Chemotherapy Resistance in Primary Acute Myeloid Leukemia By Altering Leukemia Cell Metabolism
Authors: Brea Lipe, Thomas Conley, Hani Awad, Jason H. Mendler, Jason R Myers, John M Ashton, Michael W. Becker, Omar S. Aljitawi
Journal: Blood (2018)
Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice
Authors: Hye-Sook Kwon, Aaron C. Logan, Akanksha Chhabra, Wendy W. Pang, Agnieszka Czechowicz, Keri Tate, Alan Le, Jessica Poyser, Roger Hollis, Benjamin V. Kelly, Donald B. Kohn, Irving L. Weissman, Susan S. Prohaska, Judith A. Shizuru
Journal: Blood (2019)
FRI0469 Acute and chronic effects of two different intravenous iloprost regimens in systemic sclerosis: a single centre pragmatic non-randomised trial
Authors: T. Schioppo, A. Orenti, P. Boracchi, O. De Lucia, A. Murgo, F. Ingegnoli
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> In systemic sclerosis (SSc) vascular involvement plays a pivotal role in the pathogenesis and clinical manifestations.<sup>1</sup> Intravenous (IV) iloprost (ILO), a prostacyclin analogue, is administered in SSc, according to EULAR recommendations, to improve Raynaud's phenomenon (RP) and to achieve digital ulcers (DU) healing and prevention,<sup>2</sup> even though no further indications about the regimen are specified. <h3>Objectives</h3> The aim of this study was to evaluate acute and chronic effects of IV ILO administered with two different regimens as assessed by power Doppler ultrasound (PDUS) and nailfold videocapillaroscopy (NVC) and in a group of patients not treated with ILO. <h3>Methods</h3> This was a single centre pragmatic non-randomised trial on 96 patients with SSc divided in 3 groups: no ILO (group A), ILO once monthly (group B) and ILO for 5 consecutive days every 3 month (group C). At each evaluation patients underwent PDUS and NVC. Group A patients were examined at baseline and after 3 months. Group B every month before and after IV ILO monthly therapy for 3 months. Group C before and after the 1 and 5 days of therapy at baseline and after 3 months. PDUS parameters included resistivity index (RI), finger pulp blood flow (FPBF) and periungual vascularisation. The sum of capillaries apex width in one millimetre was assessed through NVC. Results were analysed considering the average outdoor temperature at the place of residence. <h3>Results</h3> An acute IV ILO effect was observed for FPBF in group B and C (p&lt;0.001 and 0.005 respectively). An acute effect was observed for RI and periungual vascularisation only in group B. A progressive increase was observed for the other parameters without being statistically different. On the contrary IV ILO effects were not observed any longer before the following infusion. Moreover, some parameters (FPBF in group B and RI in group C) showed a statistically higher increase as low as the outdoor temperature was. <h3>Conclusions</h3> IV ILO therapy was able to cause an acute effect with respect to PDUS parameters, especially in group B. The acute effect was not any longer maintained until the following infusion. Future studies are needed to assess time for re-treating. <h3>References</h3> [1] Matucci-Cerinic M, et al. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013;65(8):1953–62. [2] Kowal-Bielecka, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1339. <h3>Acknowledgements</h3> We thank Meteo Operations Italia (MOPI) SrL – Centro Epson Meteo for providing temperature data. <h3>Disclosure of Interest</h3> None declared
Abstract MP22: Feasibility of Electrocardiographic Identification and Classification of Myocardial Infarction Using Electronic Health Records. The Atherosclerosis Risk in Communities Study (ARIC)
Authors: Antoine R Baldassari, Elsayed Z Soliman, Eric A Whitsel, Aaron R Folsom, Kunihiro Matsushita, Kenneth Butler, Brittany M Bogle, Zhu-Ming Zhang, Matthew S Loop, Gerardo Heiss
Journal: Circulation (2018)

Background: Standardized coding of 12-lead electrocardiograms (ECGs) enables an accurate classification of hospitalized myocardial infarction (MI). Although the costs of ECG coding are difficult to sustain in long-term community surveillance, automated protocols for identifying and classifying MI using electronic health records (EHR) have not incorporated ECG coding. We developed a process to retrieve and automatically code ECGs from EHR and compared its performance to ECGs coded at a specialized ECG reading center. Methods: Samples of EHR pertaining to hospitalizations previously included in hospital record abstraction and Minnesota coding of ECGs per the ARIC protocol were obtained. We assigned Minnesota codes (MCs) to the terms used by manufacturers of three ECG devices to interpret ECGs, extracted machine interpretation text from the EHR, and applied natural-language processing to match the interpretations to MCs. We defined MI by MCs as any major Q code (1.1.x, 1.2.x), or the co-occurrence of any minor Q (1.3.x) and major ST segment depression (4.1, 4.2) or T wave inversion code (5.1, 5.2). MI algorithmically ascertained from EHR was then compared to that based on MCs assigned by the ECG reading center. Results: Among 160 hospitalizations from 149 individuals admitted in 2014 to one hospital, ECG interpretations were matched to a median of three Minnesota-coded terms. There was moderate-to-substantial agreement between EHR-derived and ARIC-assigned MI by MC ( κ =0.60, 95% CI: 0.41, 0.79). Thirteen (81%) of the 16 ECGs with ARIC-assigned MCs defining MI also had EHR-derived MCs defining MI (Table 1). The corresponding specificity, positive predictive value, and negative predictive value were 0.92±0.02, 0.56±0.12, and 0.97±0.01. Conclusion: Novel, EHR-based automated approaches to electrocardiographic identification and classification of MI are feasible, relatively accurate even without pending refinements, and promise to reduce the effort and costs associated with population-based MI surveillance.
Integrated Genetic and Topological Analysis Reveals a Hodgkin-like Mechanism of Immune Escape in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Authors: Gabriel K Griffin, Margaretha G.M. Roemer, Mikel Lipschitz, Jason Weirather, Christine J. Pak, Allysa Kelly, Daniel Gusenleitner, Evisa Gjini, Bjoern Chapuy, Jie Xu, Benjamin Chen, Aliyah R. Sohani, Scott B Lovitch, Christopher Fletcher, Gordon J Freeman, Stephen Hodi, Philippe Armand, Azra H. Ligon, Margaret A. Shipp, Scott J Rodig
Journal: Blood (2018)
Abstract 18273: Frailty and Mortality in Older Patients With Acute Myocardial Infarction: Observations From the NCDR ACTION Registry-GWTG
Authors: Jacob A Udell, Di Lu, Akshay Bagai, John A Dodson, Nihar R Desai, Greg C Fonarow, Abhinav Goyal, Kirk N Garatt, Joseph Lucas, William Weintraub, Daniel Forman, Karen P Alexander, Matthew T Roe
Journal: Circulation (2017)

Introduction: Little is known about the prevalence and prognostic impact of patient (pt) frailty on in-hospital mortality in the setting of acute MI, or the optimal way to assess frailty in this setting. Methods: We examined the relationship between frailty and outcomes in acute MI pts ≥65 years from January 1, 2015 to December 31, 2016 in ACTION Registry-GWTG. Three spheres of pre-hospital function (cognition, ambulation, and functional independence) were assessed, and findings were summed in two new ways: (1) ACTION Frailty Scale based on responses to six groups adapted from the Canadian Study of Health and Aging Clinical Frailty Scale; (2) ACTION Frailty Score derived by summing a rank score of 0-2 assigned for each grade (range 0-6). Associations between frailty status and all-cause mortality were estimated using multivariable logistic regression. Results: Among 143,722 acute MI pts at 778 hospitals, 108,059 (75.2%) were fit/well and 6,484 (4.5%) were vulnerable to frailty, while 7,527 (5.2%) had mild...
PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA
Authors: Liping Tan, Dongmei Mai, Bailin Zhang, Xiaobing Jiang, Jialiang Zhang, Ruihong Bai, Ying Ye, Mei Li, Ling Pan, Jiachun Su, Yanfen Zheng, Zexian Liu, Zhixiang Zuo, Qi Zhao, Xiaoxing Li, Xudong Huang, Jie Yang, Wen Tan, Jian Zheng, Dongxin Lin
Journal: Molecular Cancer (2019)

Breast cancer is one of the most common malignancies and the major cause of cancer-related death in women. Although the importance of PIWI-interacting RNAs (piRNAs) in cancer has been increasingly recognized, few studies have been explored the functional mechanism of piRNAs in breast cancer development and progression.We examined the top 20 highly expressed piRNAs based on the analysis of TCGA breast cancer data in two patient cohorts to test the roles of piRNAs in breast cancer. The effects of piRNA-36,712 on the malignant phenotypes and chemosensitivity of breast cancer cells were detected in vitro and in vivo. MS2-RIP and reporter gene assays were conducted to identify the interaction and regulation among piRNA-36,712, miRNAs and SEPW1P. Kaplan-Meier estimate with log-rank test was used to compare patient survival by different piRNA-36,712 expression levels.We found piRNA-36,712 level was significantly lower in breast cancer than in normal breast tissues and low level was correlated with poor clinical outcome in patients. Functional studies demonstrated that piRNA-36,712 interacts with RNAs produced by SEPW1P, a retroprocessed pseudogene of SEPW1, and subsequently inhibits SEPW1 expression through competition of SEPW1 mRNA with SEPW1P RNA for microRNA-7 and microRNA-324. We also found that higher SEPW1 expression due to downregulation of piRNA-36,712 in breast cancer may suppress P53, leading to the upregulated Slug but decreased P21 and E-cadherin levels, thus promoting cancer cell proliferation, invasion and migration. Furthermore, we found that piRNA-36,712 had synergistic anticancer effects with the paclitaxel and doxorubicin, two chemotherapeutic agents for breast cancer.These findings suggest that piRNA-36,712 is a novel tumor suppressor and may serve as a potential predictor for the prognosis of breast cancer patients.
Combination of ATG and Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Peripheral Blood Stem Cell Transplants for High-Risk Hematological Malignancies- a Single Centre Experience
Authors: Shruti Prem Sudha, Eshetu G Atenafu, Queralt Salas Gay, Zoe Evans, Zeyad Al-Shaibani, David Loach, Arjun Law, Wilson Lam, Santhosh Thyagu, Fotios V. Michelis, Dennis Dong Hwan Kim, Jeffrey H. Lipton, Rajat Kumar, Auro Viswabandya
Journal: Blood (2018)
Abstract 15605: Aortic Valve Replacement Improves Survival in Moderate to Severe Aortic Stenosis and Preserved Left Ventricular Ejection Fraction Regardless of the Gradient or Flow Pattern: a Role for Early Aortic Valve Replacement?
Authors: Yujing Mo, Guy Van Camp, Giuseppe Di Gioia, Tomas Ondrus, Emanuele Barbato, Jozef Bartunek, Marc Vanderheyden, Martin Penicka
Journal: Circulation (2016)

Introduction: The role of aortic valve replacement (AVR) in patients with low gradient moderate to severe aortic stenosis (AS) (AVA ≤ 1.5 cm2) or high gradient moderate AS (AVA between 1-1.5 cm2), ...
Outcomes of Stage I and II Follicular Lymphoma in the Era of 18F-FDG PET-CT Staging: An International Collaborative Study from the Australian Lymphoma Alliance
Authors: Joshua W.D. Tobin, Gabrielle Rule, Katherine Colvin, Lourdes Calvente, David C. Hodgson, Chengetai Dunduru, Stephen Bell, James Gallo, Erica Tsang, Xuan Tan, Jessica Pearce, Jonathan Wong, Robert Campbell, Shao Yang Tneh, Sophie Shorten, Melissa Liet Hing Ng, Jacob Darch, Tara Cochrane, Constantine S. Tam, Emad Uddin Abro, Eliza Hawkes, Georgina Hodges, Dipti Talaulikar, Michael P Gilbertson, Anna Johnson, Roopesh R. Kansara, Diego Villa, Kerry J Savage, Kirk Lachlan Morris, Wojt Janowski, Sumita Ratnasingam, Robert Kridel, Chan Y. Cheah, Maher K Gandhi, Greg Hapgood
Journal: Blood (2018)